Prostate Cancer Clinical Trial

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer

Summary

99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason Score of ≤ 3+4 severity who are candidates for active surveillance and are undergoing voluntary radical prostatectomy (RP) [Cohort A] or routine prostate biopsy [Cohort B]. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 SPECT/CT imaging to correctly identify subjects with previously unknown clinically significant prostate cancer.

View Full Description

Full Description

This is a multi-center, multi-reader, open-label trial, comparing 99mTc-MIP-1404 SPECT/CT imaging in men who have had a diagnostic trans-rectal ultrasound (TRUS) guided biopsy with a histopathologic finding of Gleason score ≤3+4 who are candidates for active surveillance and are undergoing routine biopsy or voluntary RP with or without a pelvic lymph node dissection (PLND). This study will evaluate the sensitivity and specificity of 99mTc-MIP-1404 SPECT/CT image assessments to correctly identify subjects with previously unknown clinically significant prostate cancer in two cohorts: (1) Low grade prostate cancer who have elected to undergo RP [Cohort A]; and (2) very low risk (VLR) prostate cancer per 2016 NCCN Guidelines who are scheduled to undergo routine prostate biopsy [Cohort B].

Subjects will receive a single dose of 99mTc-MIP-1404 Injection (study drug) followed by whole body planar and SPECT/CT (pelvic) imaging 3-6 hours after injection. In accordance with standard of care procedures, subjects will undergo either voluntary RP [Cohort A] or prostate biopsy [Cohort B] within 42 days after study drug dosing. 99mTc-MIP-1404 image data will be collected by a central imaging core laboratory and evaluated for visible uptake within the prostate gland. These findings will then be compared against central histopathology as the truth standard. The central imaging core lab independent readers for the SPECT/CT scans will be blinded to all clinical data, including pathology results. Likewise, central pathologists are to remain blinded to all clinical data, including imaging results.

View Eligibility Criteria

Eligibility Criteria

INCLUSION CRITERIA:

Ability to provide informed consent and willingness to comply with protocol requirements
Life expectancy ≥ 6 months

Cohort A only:

A diagnostic trans-rectal ultrasound (TRUS)-guided biopsy within 12 months of enrollment showing adenocarcinoma of the prostate gland
Within 90 days of consent, serum PSA ≤ 15.0 ng/mL or ≤ 7.5 ng/mL if on 5 α-reductase inhibitors.
Candidates for active surveillance and/or a Gleason score ≤3+4
Scheduled to undergo radical prostatectomy (RP) with or without pelvic lymph node dissection (PLND)

Cohort B only:

Very low risk (VLR) prostate cancer defined by 2016 NCCN Guideline criteria:
T1c stage, and
PSA < 10 ng/mL, and
Gleason score ≤ 6 with < 3 biopsy cores cancer positive and ≤ 50% cancer in any core based on prior prostate biopsy within 24 months of enrollment, and
PSA density < 0.15 mg/mL/g
Scheduled to undergo a reassessment of prostate cancer staging that includes prostate biopsy as part of routine follow-up

EXCLUSION CRITERIA:

Subjects administered a radioisotope within 5 physical half-lives prior to study drug injection.
Previous treatment with hormonal therapy, surgery (except biopsy), radiation therapy, LHRH analogs, and non-steroidal anti-androgens, for the treatment of prostate cancer or benign prostatic hyperplasia (BPH)
Planned androgen or anti-androgen therapy prior to RP surgery or biopsy
Subjects with any medical condition or other circumstances that, in the opinion of the investigator, would significantly interfere with obtaining reliable data, achieving study objectives, or completing the study
Malignancy (not including curatively treated basal or squamous cell carcinoma of the skin) within the previous 5 years. (Ta stage transitional cell carcinoma bladder cancer with negative surveillance cystoscopy within the past 2 years may be included).

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

531

Study ID:

NCT02615067

Recruitment Status:

Completed

Sponsor:

Molecular Insight Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 43 Locations for this study

See Locations Near You

City of Hope Cancer Center
Duarte California, 91010, United States
VA Greater Los Angeles Healthcare
Los Angeles California, 90073, United States
University of California, Los Angeles
Los Angeles California, 90095, United States
University of California San Francisco
San Francisco California, 94143, United States
University of Colorado Cancer Center
Aurora Colorado, 80045, United States
Yale Cancer Center
New Haven Connecticut, 06520, United States
Florida Urology Partners - Tampa Bay
Clearwater Florida, 33612, United States
Morton Plant Hospital
Clearwater Florida, 33765, United States
University of Georgia / Regents Medical Center
Augusta Georgia, 30912, United States
University of Chicago
Chicago Illinois, 60637, United States
Louisiana State University Health Science Center
Shreveport Louisiana, 71103, United States
Johns Hopkins University
Baltimore Maryland, 21205, United States
Montgomery General Hospital
Olney Maryland, 20832, United States
Lahey Clinic
Burlington Massachusetts, 01805, United States
University of Michigan
Ann Arbor Michigan, 48109, United States
University of Minnesota
Minneapolis Minnesota, 55455, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Washington University
Saint Louis Missouri, 63110, United States
Cooper Health System
Camden New Jersey, 08103, United States
Weill Cornell Medical College
New York New York, 10065, United States
Stony Brook University Medical Center
Stony Brook New York, 11794, United States
Northeast Urology Research
Concord North Carolina, 28025, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Cleveland Clinic
Cleveland Ohio, 44195, United States
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States
Urologic Consultants of Southeastern PA, LLP
Bala-Cynwyd Pennsylvania, 19004, United States
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Thomas Jefferson University
Philadelphia Pennsylvania, 19107, United States
Fox Chase Cancer Center
Rockledge Pennsylvania, 19046, United States
Medical University of South Carolina
Charleston South Carolina, 29435, United States
Virginia Mason Medical Center
Seattle Washington, 98101, United States
University of Washington School of Medicine
Seattle Washington, 98109, United States
University of Wisconsin
Madison Wisconsin, 53792, United States
Prostate Cancer Centre
Calgary, AB Alberta, T2V 1, Canada
Lions Gate Hospital
North Vancouver British Columbia, V7L 2, Canada
Cancer Care Manitoba
Winnipeg Manitoba, R3E 0, Canada
Cancer Care Nova Scotia
Halifax Nova Scotia, B3H 2, Canada
Ottawa Hospital Research Institute, University of Ottawa
Ottawa Ontario, K1H 8, Canada
Sunnybrook Health Sciences Centre
Toronto Ontario, M4N 3, Canada
Princess Margaret Cancer Centre
Toronto Ontario, , Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Montréal Quebec, H2X 0, Canada
Jewish General Hospital
Montréal Quebec, H3T 1, Canada
MUHC
Montréal Quebec, H4A 3, Canada
Centre d'imagerie moléculaire de Sherbrooke
Sherbrooke Quebec, J1H 5, Canada
Hôtel-Dieu de Québec
Québec , , Canada

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

531

Study ID:

NCT02615067

Recruitment Status:

Completed

Sponsor:


Molecular Insight Pharmaceuticals, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider